Necrotizing soft tissue infection

Summary

Necrotizing soft tissue infection (MONDO:0018602) is a disease and 24 clinical trials. Top therapeutic interventions include sodium chloride and reltecimod. A subtype of bacterial infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 24

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	necrotizing soft tissue infection
Mondo ID	MONDO:0018602
Orphanet	440368
SNOMED CT	443928008
UMLS	C2732890
MedGen	752585
GARD	0021839
Is cancer (heuristic)	no

Also known as: NSTI

Disease family

This is a subtype of bacterial infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › necrotizing soft tissue infection

Related subtypes (51): primary bacterial infectious disease, commensal bacterial infectious disease, opportunistic bacterial infectious disease, chorioamnionitis, Clostridium difficile colitis, bacterial gastritis, bacterial arthritis, bacterial pneumonia, Whipple disease, Aeromonas hydrophila infectious disease, Pectobacterium carotovorum infection, Pseudomonas infection, septic peritonitis, bacterial infectious disease with sepsis, empyema, bacterial urinary tract infection, bacterial sexually transmitted disease, meningococcal infection, pasteurellosis, peritonsillar abscess, pneumonic pasteurellosis, tracheitis, Actinobacillus infectious disease, bacterial conjunctivitis, bacterial endocarditis, bacterial meningitis, Bifidobacteriales infectious disease, haemophilus infectious disease, Proteus infectious disease, pulpitis, rat-bite fever, Rickettsiosis, vibrio infectious disease, Yersinia infectious disease, bacterial myositis, noma, idiopathic severe pneumococcemia, mycobacterial infectious disease, escherichia coli infection, gram-negative bacterial infections, gram-positive bacterial infections, spirochaetales infections, skin disease caused by bacterial infection, staphylococcal infection, anaerobic bacteria infectious disease, Klebsiella infectious disease, fournier gangrene, botryomycosis, bacterial hemorrhagic fever, Mycoplasmoides infection, Enterococcus infectious disease

Subtypes (2): necrotizing cellulitis, necrotizing myositis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 24.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	18
PHASE3	2
PHASE2	2
PHASE4	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07489274	PHASE4	RECRUITING	Adjunctive Hyperbaric Oxygen Treatment for Patients With Necrotizing Soft-Tissue Infection (HOT-NSTI Trial).
NCT02469857	PHASE3	COMPLETED	Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections
NCT03403751	PHASE3	TERMINATED	Phase 3 Study of Reltecimod vs Placebo in Patients With Sepsis-associated Acute Kidney Injury
NCT01417780	PHASE2	COMPLETED	Evaluation of Safety, PK and Immunomodulatory Effects of AB103 in Necrotizing Soft Tissue Infections Patients
NCT02111161	PHASE2	COMPLETED	Immunoglobulin for Necrotizing Soft Tissue Infections: a Randomised Controlled Trial
NCT05157360	PHASE1/PHASE2	TERMINATED	HAT for the Treatment of Sepsis Associated With NASTI
NCT03482245	Not specified	RECRUITING	The Role of Circadian Clock Proteins in Innate and Adaptive Immunity
NCT05243966	Not specified	RECRUITING	Myriad™ Augmented Soft Tissue Reconstruction Registry
NCT06002607	Not specified	RECRUITING	Shorter Versus Extended Course of Antibiotic Therapy for Necrotizing Soft Tissue Infections
NCT06857708	Not specified	RECRUITING	The Management of Necrotizing Soft Tissue Infection Wounds With Cytal® Wound Matrix and MicroMatrix®
NCT07107555	Not specified	ENROLLING_BY_INVITATION	Necrotizing Soft Tissue Infections
NCT07120386	Not specified	RECRUITING	Irrigating vs Traditional Negative Pressure Wound Therapy to Treat Necrotizing Soft Tissue Infections
NCT01790698	Not specified	COMPLETED	Systems Medicine to Study Necrotizing Soft Tissue Infections (NSTIs).
NCT02025816	Not specified	COMPLETED	RNAseq Analysis of Microbial Gene Expression in Necrotizing Soft Tissue Infections
NCT02180906	Not specified	COMPLETED	Biomarkers in Patients With Flesh-eating Bacterial Infections
NCT02314468	Not specified	WITHDRAWN	Negative Pressure Wound Therapy and Allogeneic Human Skin Grafts for Wound Bed Preparation
NCT02483650	Not specified	UNKNOWN	Hyperbaric Oxygen Therapy Registry
NCT02501382	Not specified	COMPLETED	Modulation of Biomarkers in Patients With Flesh-eating Bacterial Infections After With Hyperbaric Oxygen Treatment
NCT03147352	Not specified	COMPLETED	Prognosis and Treatment of Necrotizing Soft Tissue Infections: A Prospective Cohort Study
NCT04801615	Not specified	UNKNOWN	Characteristics of Patients With Necrotizing Soft Tissue Infections
NCT05032625	Not specified	TERMINATED	To Evaluate the Outcomes After Surgery for Necrotizing Soft Tissue Infections
NCT05116956	Not specified	UNKNOWN	SKin and Soft Tissue Necrotizing INfections in the Intensive Care Unit: a Prospective Multi-national Cohort Study
NCT06126263	Not specified	UNKNOWN	Adjunctive Clindamycin Versus Linezolid for β-lactam Treated Patients With Invasive Group A Streptococcal Infections
NCT06629506	Not specified	COMPLETED	MicroMatrix® Flex in Tunneling Wounds

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
SODIUM CHLORIDE	4	2
RELTECIMOD	3	3